Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Inclusion Criteria: * Patients chronically infected with Hepatitis C virus (HCV) GT 1 or 4 * HCV RNA viral load ≥ 10,000 IU/mL * Naïve to prior treatment with any interferon formulation, Ribavirin (RBV) or HCV direct antiviral agent * Patients with compensated cirrhosis are permitted Exclusion Criteria: * Infected with HCV other than GT 1 or 4 * Evidence of decompensated liver disease * Documented or suspected Hepatocellular carcinoma (HCC) as evidenced by previously obtained imaging studies or liver biopsy * Evidence of a medical condition contributing to chronic liver disease other than HCV * History of chronic Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV) * Current or know history of cancer (except in situ carcinoma of cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment * Laboratory values: 1. Hemoglobin \< 12 g/dL (females) or \< 13 g/dL (males) 2. Platelets \< 90 x 1000000000 cells/L 3. Absolute neutrophil count (ANC) \< 1.5 × 1000000000 cells/L 4. Total bilirubin ≥ 34 µmol/L (unless due to Gilbert's disease)